- Home
- RLMD vs VERU Comparison
RLMD vs VERU Comparison
Compare RLMD & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- VERU
- Stock Information
- Founded
- RLMD 2004
- VERU 1971
- Country
- RLMD United States
- VERU United States
- Employees
- RLMD N/A
- VERU N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- VERU Health Care
- Exchange
- RLMD Nasdaq
- VERU Nasdaq
- Market Cap
- RLMD 66.7M
- VERU 54.6M
- IPO Year
- RLMD N/A
- VERU 1990
- Fundamental
- Price
- RLMD $1.99
- VERU $4.29
- Analyst Decision
- RLMD Hold
- VERU Strong Buy
- Analyst Count
- RLMD 2
- VERU 3
- Target Price
- RLMD $1.00
- VERU $33.33
- AVG Volume (30 Days)
- RLMD 517.7K
- VERU 158.4K
- Earning Date
- RLMD 11-06-2025
- VERU 08-12-2025
- Dividend Yield
- RLMD N/A
- VERU N/A
- EPS Growth
- RLMD N/A
- VERU N/A
- EPS
- RLMD N/A
- VERU N/A
- Revenue
- RLMD N/A
- VERU $16,886,419.00
- Revenue This Year
- RLMD N/A
- VERU N/A
- Revenue Next Year
- RLMD N/A
- VERU N/A
- P/E Ratio
- RLMD N/A
- VERU N/A
- Revenue Growth
- RLMD N/A
- VERU 337.24
- 52 Week Low
- RLMD $0.24
- VERU $2.64
- 52 Week High
- RLMD $3.98
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- RLMD 59.73
- VERU 74.55
- Support Level
- RLMD $1.89
- VERU $3.75
- Resistance Level
- RLMD $2.84
- VERU $3.99
- Average True Range (ATR)
- RLMD 0.28
- VERU 0.24
- MACD
- RLMD 0.01
- VERU -0.01
- Stochastic Oscillator
- RLMD 37.96
- VERU 94.34
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.